基本資料
種類: ETF
費用比率%: 0.44
資產淨值: 171.02
成立日期: 05/02/2001
 
分析
市值分佈:
87.19%
大市值
8.91%
中市值
3.58%
小市值
持股比例加總可能不達100%,原因包括ETF持有現金或衍生工具。
 
 
行業分佈 國家/地區分佈
 
投資組合
 (更新時間: 07/03/2026 05:58) 總持有投資項目: 251  
0%
 
100%
     10大 (49.74%)
代號 名稱 佔比% 持有日期
VNDAVanda Pharmaceuticals0.0428/02/2026
FULCFulcrum Therapeutics0.0428/02/2026
PSNLPersonalis0.0428/02/2026
OPKOPKO Health0.0428/02/2026
PACBPacific Biosciences of California0.0428/02/2026
ALLOAllogene Therapeutics0.0428/02/2026
MGTXMeiraGTx Holdings plc0.0428/02/2026
FDMT4D Molecular Therapeutics0.0428/02/2026
ALVOAlvotech0.0428/02/2026
PRMEPrime Medicine0.0428/02/2026
BBOTBridgeBio Oncology Therapeutics Inc0.0428/02/2026
LXEOLexeo Therapeutics0.0428/02/2026
LCTXLineage Cell Therapeutics0.0428/02/2026
RGNXREGENXBIO0.0428/02/2026
LABStandard BioTools0.0428/02/2026
EBSEmergent BioSolutions Inc.0.0428/02/2026
MYGNMyriad Genetics0.0328/02/2026
ADCTADC Therapeutics SA0.0328/02/2026
KROSKeros Therapeutics0.0328/02/2026
ENTAEnanta Pharmaceuticals0.0328/02/2026
  1    2    3    4    5    6    7    8    9   10    11    12    13  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.